The MYC inhibitor 361 (MYCi361) suppressed the tumor growth of MycCaP PC cell lines in mice, increased the tumor immune cell infiltration, upregulated PD-L1 on tumor cells, and sensitized cancer to anti-PD-1 immunotherapy [211]. Here, CD274 is linked to cancer.